Anti-Cancer Drugs to Get Up to 70% Cheaper From November 9

The government has introduced trade-margin controls covering 137 identified non-scheduled anti-cancer drugs, with maximum retail prices expected to fall by up to 70 per cent for affected medicines. The National Pharmaceutical Pricing Authority issued the notification on October 17, 2026, invoking Paragraph 19 of the Drugs (Prices Control) Order, 2013. The revised prices for the anti-cancer drugs are scheduled to take effect on November 9, 2026.

Under the notification, trade margins for the covered anti-cancer drugs will be restricted to 30 per cent under the prescribed pricing framework. The government expects the intervention to reduce the maximum retail prices of affected medicines by as much as 70 per cent, although the actual reduction will vary according to existing prices and the applicable calculation. Manufacturers must submit revised prices to the NPPA price control regulator within seven days of the notification's publication.

The trade margin rationalisation exercise follows recommendations from an expert committee constituted under the Directorate General of Health Services, which considered medicines for inclusion based on affordability and public-health objectives. The DPCO 2013 drug pricing framework allows government intervention in drug prices under specified circumstances in the public interest.

Medicines highlighted in the government's announcement include pembrolizumab, durvalumab and osimertinib. The broader list also covers drugs such as denosumab, pegfilgrastim and bevacizumab, used in different cancer-related treatment settings. The inclusion of these specialised medicines is significant because certain anti-cancer drugs can involve substantial expenditure over a course of therapy.

The latest cancer drug price cut builds on an earlier trade margin rationalisation exercise introduced in 2019, when controls were applied to 42 selected non-scheduled anti-cancer medicines. According to the government, that initiative resulted in reductions of up to 90 per cent in the MRPs of 526 brands.

Anti-Cancer Drugs: What the Notification Covers

The notification covers 137 identified non-scheduled anti-cancer drugs recommended for inclusion following expert review, including immunotherapy and other specialised therapies. The cancer drug price cut will not apply uniformly: the government has cautioned that the expected reduction of up to 70 per cent is an estimate for affected products, not a blanket promise for every medicine or every patient's total treatment bill. Patients should consult the official notification for the complete list and applicable formulations.

Why Anti-Cancer Drugs Needed Price Intervention

The cost of cancer treatment can place significant financial pressure on patients and their families, particularly when treatment requires expensive specialised medicines over an extended period. Trade margins represent the difference between a product's acquisition cost and its subsequent selling price within the distribution chain, and where margins are high, the price paid by patients may substantially exceed the price at which a medicine enters distribution. The NPPA price control move is intended to address excessive mark-ups and improve access to treatment by making the covered medicines more affordable.

Anti-Cancer Drugs: When and How the New Prices Apply

The revised prices are scheduled to take effect on November 9, 2026. Pharmacies and hospitals will be required to charge the revised prices from the implementation date and display the applicable prices at their establishments, with hospitals also required to display them prominently on their websites. Consumers can consult the NPPA's official website and its Pharma Sahi Daam application to check medicine-price information under the DPCO 2013 drug pricing framework. If a covered medicine continues to be sold above the permitted price after November 9, patients can seek clarification from the seller and approach the regulator's official grievance channels.